Phenytoin-folic acid: a review

Area of Science:

• Nutritional Biochemistry
• Pharmacology
• Clinical Medicine

Background:

• Phenytoin is an anticonvulsant medication with a known interaction with folate.
• Long-term phenytoin therapy frequently leads to folate deficiency.
• While megaloblastic anemia is a rare complication, nonanemic folate deficiency may still pose risks.

Purpose of the Study:

• To elucidate the mechanisms behind phenytoin-induced folate depletion.
• To investigate the consequences of folic acid supplementation in folate-deficient patients on phenytoin therapy.
• To understand the impact on phenytoin serum concentrations and seizure control.

Main Methods:

• Review of existing literature on folate-phenytoin interactions.
• Analysis of proposed mechanisms for folate depletion by phenytoin.
• Examination of studies reporting outcomes of folic acid supplementation in patients on phenytoin.

Main Results:

• Phenytoin can deplete body folate through several proposed mechanisms.
• Folic acid supplementation in folate-deficient patients on phenytoin can decrease phenytoin serum concentrations.
• This reduction in phenytoin levels may lead to a loss of seizure control.
• Folate's role in hepatic metabolism of phenytoin is suggested, with individualized effects on elimination kinetics.

Conclusions:

• The interaction between folate and phenytoin is bidirectional and clinically significant.
• Careful consideration is needed when supplementing folic acid in patients taking phenytoin.
• Individualized monitoring of phenytoin levels and seizure control is recommended during folate supplementation.